

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 38/10, 38/04	A1	(11) International Publication Number: WO 95/30431 (43) International Publication Date: 16 November 1995 (16.11.95)
(21) International Application Number: PCT/US95/05422 (22) International Filing Date: 2 May 1995 (02.05.95) (30) Priority Data: 08/240,973 9 May 1994 (09.05.94) US 08/343,331 21 November 1994 (21.11.94) US (71)(72) Applicant and Inventor: BINDER, William, J. [US/US]; Suite 809, 9201 Sunset Boulevard, Los Angeles, CA 90069 (US). (74) Agents: ZAITLEN, Richard, H. et al.; Spensley Horn Jubas & Lubitz, 5th floor, 1880 Century Park East, Los Angeles, CA 90067 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <div data-bbox="812 777 1274 903">AMI INFORMATION SERVICES P.O. BOX 405, CORTE MADERA, CA 94976-0405 (415) 927-0340 • FAX (415) 927-7250</div>
(54) Title: METHOD FOR REDUCTION OF HEADACHE PAIN (57) Abstract <p>The invention is a method for reducing headache pain and symptoms associated with the onset or occurrence of headache in mammals. The method is performed by delivering an invertebrate presynaptic neurotoxin to a mammal extramuscularly (preferably at a localized, site of pain), or at a site in one or more muscles (preferably muscles of the face, cranium and neck). The presynaptic neurotoxins administered according to the invention are those neurotoxins that are known to produce a reversible, flaccid paralysis of muscle tissue in mammals. The preferred neurotoxin for use in the method of the invention is Botulinum toxin, particularly Botulinum toxin A.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

METHOD FOR REDUCTION OF HEADACHE PAIN

RELATED PATENT APPLICATIONS

This is a continuation-in-part of U.S. Patent Application Serial No.

5 08/240,973, filed June 29, 1994.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to the pharmacological treatment of headache pain.

More specifically, the invention relates to the reduction of pain associated with
10 headaches through localized administration of a therapeutically effective dosage of
pharmaceutically safe invertebrate exotoxin, in particular Botulinum toxin A.

2. History of the Prior Art

"Headache" is a term which encompasses a relatively vast spectrum of
common symptoms and sometimes obscure causes. Headaches may be associated
15 with emotional states such as depression and tension, as well as physical events
such as muscular tension, neuralgia, neuropathy and vascular disturbances.
Although a patient may experience more than one kind of headache pain, the
various manifestations of headache are generally believed to have different
pathological origins (but see, Olesen, *et al.*, *Pain*, 46:125-132, 1991 [a model, albeit
20 one unaccepted in the art, which proposes that tension headache shares a causal
myofascial component with migraine]). For example, it is generally accepted in the
art that the headache condition known as migraine is directly related to vascular
changes and events attributable to contraction of the smooth muscles of blood
vessels (see, e.g., Wolff, *et al.*, "Headache and Other Head Pain", 1963; and Table
25 1(a), Row 1), while tension headache originates in skeletal (striated) muscular
stress (Table 1(a), Row 2) and other headache pain stems principally from
neurological disorders (see, e.g., Table 1(b)). Although therapies intended to
alleviate headache symptoms are abundant, the efficacy of such treatments varies
widely.

30 The most common types of headache, together with the perceived
pathological origin of the pain and conventional methods for treatment, are
summarized in Tables 1 (a)-(b) below:

-2-

TABLE 1(a)
HEADACHES NOT PRIMARILY ASSOCIATED
WITH DISORDERS OF THE FACIAL AND CRANIAL NERVES

5	Type	Presumed Mechanism	Site	Common Treatment
10	Migraine (vascular headache)	Vascular dilation resulting in changes to cerebral blood flow; possible hor- monal origin	Fronto temp- oral (uni- or bilateral)	Ergot preparations, analgesic, anti- inflammatory medi-cat- ions, and serotonin modu- lators
	Tension headache	Vascular disturbance and muscle spasm or fatigue (the latter is not believed to be the primary origin of pain)	Generalized	Analgesic, anti-infla- mmatory, anti- anxiety and antidepres- sant medication
	Meningeal irritation	Meningitis	Generalized	Treat the underlying disease
15	Brain tumor	Cancer	Varies	Treat the underlying disease
	Temporal arteritis	Arterial disorders	Unilateral, temporal, occipital	Cortico- steroids
20	Traumatic headache	Head injuries resulting in subdural hematoma, dysa- utonomic cephalalgia or other disorders	Varies depending on origin	Varies depending on ori- gin

TABLE 1(b)
HEADACHES PRIMARILY ASSOCIATED
WITH DISORDERS OF THE FACIAL AND CRANIAL NERVES

5

10

15

Trigeminal neuralgia	Trigeminal nerve, unilateral	Idiopathic, vascular disturbances, multiple sclerosis, tumor	Carbamazepine
Atypical facial neuralgia	Unilateral or bilateral	Depressive, anxiety states, idiopathic	Anti-depressant and anti-anxiety medication
Orbitally related neuralgias	Unilateral in eye, cheek, ear, neck	Idiopathic, paranasal disorders	Decongestant nasal medication
Tolosa-Hunt Syndrome	Unilateral, mainly orbital	Arteritis and granulomatous lesions	Corticosteroid therapy
Reader's paratrigeminal syndrome	Unilateral, frontotemporal and maxilla	Tumors, granulomatous lesions	Varies depending on origin
Postzoster syndrome	Unilateral, trigeminal divisions	Herpes zoster	Carbamazepine and anti-depressants
Costen's syndrome	Unilateral, near temporomandibular joints	Loss of teeth, rheumatoid arthritis	Bite correction, arthritis related therapies

(Tables 1(a) and 1(b) are adapted from *Harrison's Principles of Internal Medicine*, 11th Ed., Chapter 6, Tables 6-1 and 6-2 (McGraw-Hill, 1987)).

20

25

One therapeutic modality for certain neuromuscular disorders which has begun to gain acceptance in recent years is the administration of invertebrate exotoxins in a pharmaceutically safe form. For example, serotype A of the Botulinum toxin has been recommended in the art for use for the treatment of certain diseases such as disorders of the extraocular muscles (e.g., comitant strabismus and nystagmus) as well as dystonias (involuntary contractions of facial muscle) (see, e.g., *The New England Journal of Medicine*, 324: 1186-1194, 1991). The advantage of using Botulinum toxin A in this context is that it produces a reversible, flaccid paralysis of mammalian skeletal muscle, presumably by blocking the

-4-

exocytosis of acetylcholine at peripheral, presynaptic cholinergic receptors, with limited activity at receptors in the central nervous system (Rabasseda, *et al.*, *Toxicon*, 26:329-326, 1988). Additionally, Botulinum toxin A is not believed to result in degeneration of nervous or muscular tissue and has been approved for use in
5 certain therapies by the U.S. Food and Drug Administration.

Botulinum toxin A is also presently being tested for its ability to cause the removal of hyperfunctional lines of the face. These tests have demonstrated that Botulinum toxin A may be administered into the musculature of the face without toxic effect to produce localized relaxation of skeletal muscle that lasts as long as six
10 months (Blitzer, *et al.*, *Otolaryngol Head and Neck Surg.*, 119:1018-1023, 1993).

Other serotypes of the Botulinum toxin have been identified that have immunologically distinct phenotypes; i.e., serotypes B, C1, C2, D, F and G (Simpson, *et al.*, *Pharmacol.Rev.*, 33:155-188, 1981). All of the serotypes are believed to be proteins of about 150 kDa molecular weight that are comprised of two
15 polypeptide chains linked by disulfide bridges. The shorter of the two chains is believed to be responsible for the toxicity of the toxin, while the longer of the two chains is believed to be responsible for the penetration of the toxin into nervous tissue. Although antigenically different to some extent, the Botulinum serotypes are believed to be similar in their pharmacological actions (Brin, *et al.*, "Report of the
20 Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", *Neurology*, 40:1332-1336, 1990).

In addition, like serotype A, serotypes B and E of the Botulinum toxin have been linked to cases of botulism in humans. Thus, having the same pathological activity as serotype A, serotypes B and E can be reasonably expected to have the
25 same therapeutic activity as serotype A in the method of the invention.

Other invertebrate toxins are known, or can reasonably be expected, to share the mode of action of Botulinum toxin and/or the toxin's ability to produce reversible, flaccid paralysis of muscles where the toxin is introduced. For example, serotypes A and E of the Botulinum toxin share a substantial degree of sequence homology with
30 the Tetanus neurotoxin produced by *Clostridium tetani* (DasGupta, *et al.*, *Biochemie*, 71:1193-1200, 1989). Further, although the tetanus neurotoxin typically acts on the central nervous system to produce rigid rather than flaccid muscle paralysis, at least

-5-

one peptide digestion fragment of the tetanus toxin (fragment Ibc, which is produced as a papain cleavage product) have been shown to act peripherally to produce flaccid paralysis (Fedinic, *et al.*, *Boll. Ist. Sieroter Milan*, 64: 35-41, 1985; and, Gawade, *et al.*, *Brain Res.*, 334:139-46, 1985).

5 Another promising exotoxin-based therapy is the use of *Staphylococcal alpha-toxin* to stimulate the production of a naturally occurring brain component known as muscle-relaxing factor (MRF). Recently, researchers injected 1 microgram of *Staphylococcal alpha-toxin* into mice and detected elevated levels of MRF in serum and brain tissue. Reversible, flaccid paralysis of skeletal muscle in
10 the injected mice was also observed (Harshman, *et al.*, *Infect. Immun.*, 62:421-425, 1994), indicating that *S. alpha-toxin* also shares the mode of action of Botulinum toxin.

Reversible, flaccid paralysis has also been observed following intrathecal injection of acylpolyamine toxins, anticholinergic, presynaptic neurotoxins that are
15 produced in the venom of many invertebrates (Herold, *et al.*, *Anesthesiology*, 77:507-512, 1992). In particular, two toxins (AR636 and AG489) from spiders *Argiope aurantia* and *Agelenopsis aperta* have been shown to produce motor inhibition at a dosage of 2 micrograms while 7 micrograms was an effective dosage to produce sensory inhibition. Despite the apparent effects of such exotoxins on
20 motor and sensory activity in mammals, the use of such toxins in humans to date has been limited. Further, proposals for additional applications for exotoxins use have not included extramuscular applications generally or use in reduction of headache pain specifically.

SUMMARY OF THE INVENTION

25 The invention provides a method for reducing headache pain and symptoms in mammals, particularly humans. Specifically, the invention comprises administering a therapeutically effective amount of a pharmaceutically safe invertebrate presynaptic neurotoxin to a mammal. The preferred routes of administration are by extramuscular injection, such as into the perimuscular areas of the face, cranium
30 and neck, as well as into localized sites of pain in these areas. Additional therapeutic benefits can be expected from administering the presynaptic neurotoxins

-6-

of the invention into one or more striated muscles of the face, cranium and/or neck (including muscles of the shoulder region) muscles in the back.

The presynaptic neurotoxins of the invention will be those neurotoxins that can be administered to a mammal to produce localized paralysis of musculature that is reversible (although such paralysis need not necessarily be induced in the practice of the invention) and does not result in degeneration of muscle or nervous tissue. The preferred presynaptic neurotoxin of the invention is Botulinum toxin A.

Surprisingly, the method of the invention may not only be applied to reduce headache pain associated with muscle spasm or contraction, but may also be utilized to reduce headache pain associated with vascular disturbances, neuralgia and neuropathy. Even more surprisingly, it has been discovered that reduction of headache pain (particularly vascular headache pain) can be achieved through extramuscular administration of the presynaptic neurotoxins of the invention; i.e., without producing flaccid paralysis of muscle. The method may also be used to reduce symptoms associated with certain kinds of headache pain, such as the premonitory aura experienced by many migraine sufferers.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a anatomical drawing depicting the musculature of the human face, cranium and neck. Common target sites (i.e., areas of localized headache pain) are circled; (1) is the frontal and glabella region, (2) is the temporal (right) region, and (3) is the suboccipital region.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A. PRESYNAPTIC NEUROTOXIN COMPOSITIONS FOR USE IN THE METHOD OF THE INVENTION

"Presynaptic neurotoxin" as used in this disclosure refers to both invertebrate toxins and biologically active peptide fragments of proteinaceous invertebrate toxins. The presynaptic neurotoxins of the invention will be those neurotoxins that are known to produce localized, flaccid paralysis of musculature in mammals that is reversible and does not result in degeneration of muscle or nervous tissue.

It will be appreciated, however, that the reduction of headache pain which may be achieved according to the method of the invention is apparently independent of the induction of flaccid muscular paralysis which the presynaptic

- 7 -

neurotoxins of the invention will produce. Specifically, as described further below, reduction of headache pain may be achieved at dosages of presynaptic neurotoxin which are lower or higher than dosages required to produce flaccid paralysis of skeletal muscle and without introduction of the neurotoxin into muscle tissue.

5 The preferred presynaptic neurotoxin of the invention is Botulinum toxin. Serotype A of this toxin is commercially available and is presently supplied by Allergan, Inc. of Irvine, California under the tradename "BOTOX and by Porton Products Ltd, of the United Kingdom under the tradename "DYSPORT". A pentavalent toxoid of all eight known Botulinum serotypes is also available as an
10 investigational drug from the U.S. Center for Disease Control in Atlanta, Georgia. Of these, the Botulinum A toxin preparations are most preferred for their known safety and efficacy.

 Tetanus toxins for use as vaccines are also commercially available (from, for example, Lederle Laboratories of Wayne, New Jersey under the tradename
15 "TETANUS TOXOID PUROGENATED"). As discussed above, the Ibc fragment of the Tetanus toxin is believed to act peripherally and is therefore likely to be similar in its activity to Botulinum toxin. Therefore, the method of the invention will preferably encompass the use of pharmaceutically safe forms of the Ibc fragment of the Tetanus toxin rather than the use of intact Tetanus toxin.

20 Those of ordinary skill in the art will know, or can readily ascertain, how to obtain the presynaptic neurotoxins of the invention, including the Botulinum and Tetanus toxoids, in a pharmaceutically safe form; preferably, a form that is nontetragenic and does not induce a detectable immune response to the toxin antigen. For most of the presynaptic neurotoxins of the invention, pharmaceutical
25 safety will be dose-dependent such that relatively low dosages of toxin will be "safe" as compared to dosages which are known to be sufficient to produce disease.

 Preferably, the presynaptic neurotoxins of the invention will be administered as a composition in a pharmaceutically acceptable carrier. To that end, presynaptic neurotoxin compositions are prepared for administration by mixing a toxin the
30 desired degree of purity with physiologically acceptable sterile carriers. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the presynaptic

-8-

neurotoxin with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Such compositions may also be lyophilized and will be
5 pharmaceutically acceptable; i.e., suitably prepared and approved for use in the desired application.

Most preferably, the presynaptic neurotoxin will be formulated in unit dosage form for ease of administration. For example, the presynaptic neurotoxin may be supplied as a sterile solution or lyophilized powder in a vial.

10 **B. METHODS FOR ADMINISTRATION OF THE PRESYNAPTIC NEUROTOX-
INS OF THE INVENTION**

Generally, the dose of presynaptic neurotoxin to be administered will vary with the age, presenting condition and weight of the mammal to be treated. The potency of the presynaptic neurotoxin will also be considered. Toxin potency is
15 expressed as a multiple of the LD₅₀ value for a reference mammal, usually a mouse. Where a mouse is the reference mammal, one "unit" of toxin is the amount of toxin that kills 50% of a group of mice that were disease-free prior to inoculation with the toxin. For example, commercially available Botulinum toxin A typically has a potency such that one nanogram contains about 40 mouse units. The potency in
20 humans of the Botulinum toxin A product supplied by Allergan, Inc. under the registered trademark "BOTOX" is believed to be about LD₅₀=2,730 units.

Assuming a potency which is substantially equivalent to LD₅₀=2,730 units, the presynaptic neurotoxin can be administered in a dose of up to about 1,000 units, although individual dosages of about 15-30 units are preferred and dosages of as
25 low as about 2.5 to 5 units will have therapeutic efficacy. Generally, the presynaptic neurotoxin will be administered as a composition at a dosage that is proportionally equivalent to about 2.5 cc/100 units. Those of ordinary skill in the art will know, or can readily ascertain, how to adjust these dosages for presynaptic neurotoxin of greater or lesser potency.

-9-

Preferably, the lowest therapeutically effective dosage (i.e., the dosage which results in detection by the patient of a reduction in the occurrence and/or magnitude of headache pain experienced by the patient, even though other symptoms associated with the pain, such as the premonitory aura associated with vascular headache, may persist) will be injected. In the initial treatment, a low dosage may be administered at one site to determine the patient's sensitivity to, and tolerance of, the neurotoxin. Additional injections of the same or different dosages will be administered as necessary. For example, if headache pain predominates in the frontal cranial region (see, FIGURE 1), the patient may receive up to 40 units in the glabella region, and may also receive up to 40 units of the neurotoxin in the mid-forehead region. For headache pain which predominates temporally, laterally and/or suboccipitally, the initial dosage (to be administered extramuscularly) will usually be somewhat lower; e.g., about 10 units per site, followed by up to 40 units per side.

For many indications (particularly vascular headaches), extramuscular injection will be the most efficacious route of administration as well as a route which avoids the risk of trauma to muscle tissue. Such injection may, for example, be made subcutaneously or, preferably, perivascularly (to produce infiltration of the neurotoxin into tissue at the target site). If possible, such injections will be made at a localized site of pain associated with the patient's presenting condition ("target site"); e.g., temporal, frontal and/or suboccipital sites in vascular headaches.

Those of ordinary skill in the art will be familiar with such target sites and their pathological relationship to headache pain. For example, localized sites of pain known to be associated with the onset of migraine are the oculo-frontal-temporal area of the face and the forehead, with the former predominating in the early stages of migraine onset (see, e.g., Sjaastad, *et al.*, *Func.Neurol.*, 8:27-32, 1993 [fronto-temporal pain is a typical trait of classical migraine]; this reference is incorporated herein by this reference to illustrate knowledge in the art regarding localized sites of headache pain). Common target sites are identified in FIGURE 1.

-10-

The preferred target site for injection of the presynaptic neurotoxin will be in or near the or extramuscular regions, in particular, target sites of the face, cranium and neck (see, FIGURE 1). Although the precise mechanism by which the method of the invention reduces headache pain is not known, it is believed that the efficacy
5 of the method is not necessarily dependent on whether muscle spasm or strain is present in the patient or causally related to the headache pain experienced by the patient.

For example, as shown in the data presented in the Examples, the method of the invention was effective in reducing headache pain even in persons who only
10 received an extramuscular injection of presynaptic neurotoxin. Moreover, reduction of headache pain was unexpectedly observed even in patients whose pain was causally related to vascular or neurological components; e.g., classical migraine, trigeminal neuralgia and trauma headache. However, those of ordinary skill in the art will recognize that additional therapeutic benefits may be achieved through
15 introduction of the presynaptic neurotoxins of the invention into musculature (particularly in the back) where muscle spasm or strain is present. The most preferred target sites are the bilateral temporal, frontal, glabella, and suboccipital areas of the face (see, FIGURE 1). The corrugator, procerus, temporal and frontalis muscles are also suitable sites for introduction of the presynaptic neurotoxins of the
20 invention. Localized paralysis in any injected muscle can be monitored visually, by the patient's description of post-injection mobility at the target site musculature, as well as by electromyographical signals obtained at the time of administration of the neurotoxin. For introduction into extramuscular target sites, the presynaptic neurotoxins of the invention will conveniently be administered by injection.

25 For intramuscular injections, to ensure that the presynaptic neurotoxin is delivered to the target site without substantial systemic distribution, the use of electromyographical ("EMG") injection is recommended. A preferred technique for EMG injection is to introduce the presynaptic neurotoxin through a monopolar hollow bore needle (commonly, one which is coated with a non-stick surface such as
30 "TEFLON", a trademarked product of DuPont Nemours, of Massachusetts). The

-11-

needle is placed through the skin and into the target site of a muscle, preferably at a neuromuscular junction. Once the needle has been inserted, the most active site of the muscle can be determined by observation of the EMG signal. Those of ordinary skill in the art will know of, or can readily ascertain, other suitable techniques for administering EMG injections.

The injections will be repeated as necessary. As a general guideline, Botulinum toxin A administered into or near muscle tissue according to the method of the invention has been observed to produce flaccid paralysis at target site muscles for up to about 3 to 6 months. Reduction of headache pain in patients who received the presynaptic neurotoxins of the invention extramuscularly has also persisted for extended periods of time. However, Botulinum A toxin in particular is expected to be most effective when administered according to the method of the invention at about 3 month intervals.

The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended claims.

In the examples, the abbreviation "min" refers to minutes, "hrs" and "h" refer to hours, "mo" and "mos" refers to months, "yr" and "yrs" refer to years, and measurement units (such as "ml") are referred to by standard abbreviations. Also, "F" refers to female and "M" refers to male. Further, in Examples I and II, the following symbols indicate trademarks of the companies listed below:

- Trademarked product of Sandoz Pharmaceuticals.
- Trademarked product of Bristol-Myers Laboratories
- ■ Trademarked product of Stuart Pharmaceuticalus
- 25 ■ ■ ■ Trademarked product of Syntex Pharmaceuticals
- ■ ■ ■ Trademarked product of Merck, Sharp & Dohme Pharmaceuticals
- ■ ■ ■ ■ Trademarked product of Schering Drug
- Trademarked product of Winthrop-Breon
- Trademarked product of Eli Lilly Pharmaceuticals
- 30 * Trademarked product of Roche Products

- 12 -

† Trademarked product of DuPont

■ Trademarked product of Ayerst Pharmaceuticals

j Trademarked product of Cerenex Pharmaceuticals

5

EXAMPLE I**ADMINISTRATION OF BOTULINUM TOXIN A
TO REDUCE HEADACHE PAIN IN HUMANS**

Over a period of 6 months, 162 patients received 1 to 2 injections of Botulinum toxin A ("BOTOX"), reconstituted with saline to a concentration of 2.5
10 cc/100 units. The toxin was administered intramuscularly by EMG injection into the frontalis, corrugator, procerus and/or platysma muscles of the face. The patients were participants in a clinical trial of the use of Botulinum toxin A to temporarily remove facial wrinkles.

Of the patients who received the injections, 11 spontaneously reported a prior
15 case history of headache pain ("headache group" patients). Of the headache group patients, 5 had a prior history of migraine, 1 had previously been diagnosed as having trigeminal neuralgia, and the remainder suffered from frequent "tension" headaches (i.e., at an occurrence of at least 3 times a week). Of the patients reporting a prior history of migraine, two reported that they were suffering from an
20 attack at the time that the injection was administered. One of these patients was experiencing headache pain, while the other was experiencing premonitory symptoms of migraine; i.e., a visual aura. The patient with trigeminal neuralgia had previously been treated pharmacologically without substantial reduction of her symptoms.

25 All of the 11 patients in the headache group reported that they were either free of headaches or suffered substantially reduced headache pain (as evaluated subjectively by the patient) for periods of up to 6 months following treatment. The two patients who had reported that they were experiencing migraine symptoms at the time of treatment reported that the symptoms completely dissipated after 1 to 1
30 1/2 hrs.

Additional details of the case history, treatment, and post-treatment history of patients within the headache group who agreed to provide such information are

TABLE 2

Age/ Sex		Presenting Condition	Prior Treatment	Site of Delivery	Dosage and Frequency of Injection	Post Injection Condition
42/F		Periodic migraines over 7-8 years	CAFERGOT [®] (ergotamine tartrate)	Corrugator and procerus	12 units, 1 time; 15 units, 1 time. Administered over a 7 mos interval.	No migraine pain for 7 mos
42/F		Severe migraine, at about 2 week intervals since age 8 years	STADOL [®] (butor- phanoltartrate) analgesic and ELAVIL [®] 4 times/day (anti- depressant) and NAPROSYN [®] at 500 mg/day (anti- inflammatory)	Corrugator and procerus	16 units, 3 times; 22 units, 2 times. Administered over a 3 mos interval.	No migraine pain for 3 mos.; one at- tack ended 1h, 15 min after dosing; on 2nd occasion pain at end of migraine cycle ended 30 min after dosing
38/F		Migraine sufferer, no detail available re history	No detail available	Corrugator and procerus	16 units, 1 time; 20 units, 1 time. Administered over about a one mos interval.	No migraine pain for more than six months

-14-

Age/ Sex		Presenting Condition	Prior Treatment	Site of Delivery	Dosage and Frequency of Injection		Post Injection Condition
44/F		Tension headache about 1/week for 10 years. Most pain in left temporal region. Some joint pain on left side of jaw.	Acetaminophren (500 mg)	Corrugator, procerus and frontalis	16 units, 1 time to the frontalis; 15 units, 1 time to the corrugator and procerus. Administered at the same time.		No headache pain for 3 months in left temporal region. Joint pain also re-lieved but pain occurred once in the right tempo- ral region
36/F		Daily tension head- aches of moderate to severe intensity for more than 4 years	INDOCIN SR ***** (75 mg) (indometh- acin)	Corrugator and procerus	16 units, 1 time		Some reduction of pain

SUBSTITUTE SHEET (RULE 26)

-15-

Age/ Sex	Presenting Condition	Prior Treatment	Site of Delivery	Dosage and Frequency of Injection	Post Injection Condition
47/F	Migraine at about 1-2 month intervals and tension or si- nus headache daily	Analgesic tablets, VANCEN- ASE***** (beclo- methasone)	Corrugator and procerus	16 units, 2 times to the corrugator and procerus; 12 units, 1 time to the corrugator and procerus; 20 units, 1 time to the bilateral temporal areas. Administered over a 4 mos interval.	No migraine for 4 months. Other headache pain down to about 3 day intervals
41/F	Migraine at about 6 week intervals with premonitory aura and tension head- ache at about 1 week intervals	Codeine	Corrugator and procerus	1 dose of 16 units.	No migraine for one month but other headache pain more frequent

SUBSTITUTE SHEET (RULE 26)

-16-

Age/ Sex		Presenting Condition	Prior Treatment	Site of Delivery	Dosage and Frequency of Injection	Post Injection Condition
40/F		Tension headaches several times a week	Aspirin	Corrugator and procerus and frontalis	15 units, 3 times corrugator and procerus; 20 units, 1 time, frontalis; 10 units, bilateral temporal areas. Administered over a 6 mos interval.	No headache pain for one year
58/F		Tension headache associated with premenstrual cycle	Ibuprofen	Corrugator, procerus and frontalis	10 units, 1 time to corrugator and procerus; 16 units, 2 times to corrugator and procerus; 16 units, 1 time to frontalis; 20 units, 1 time to frontalis. Administered over a 5 month period.	No headache pain for approximately 3 mos.

-17-

EXAMPLE II

Additional patients ("pt.") were treated using the method described in Example I, with particular emphasis on extramuscular injections of the Botulinum A toxin in the frontal, suboccipital and temporal regions of the face. The only adverse effect of the
5 injection reported by any patient was soreness at the injection site, particularly at intramuscular injection sites. The results of the treatment received by each patient are reported in Table 3, below.

TABLE 3

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
42/F	•Cafergot	12 units, Glabella 5/7/93; 5 units, Glabella 10/29/93	Has had severe headaches (possibly of migraine origin) for the last 7-8 years without premonitory symptoms. Bright lights, loud noises, dairy products intensify pain.	As of 11/93: the pt. was quoted as saying: "Since I received the BOTOX, almost 6 months ago, my migraines [headaches] have been completely eliminated." NOTE: Most of the pt.'s corrugator muscle function returned 3 months after the injection, although pt. had has not had headache pain for another 3 after muscle function returned..

-19-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
42/F	Stadol - now. In past - Cafergot	16 units, Glabella 10/23/92; 16 units, Glabella 6/1/93; 10 units, Forehead 6/30/93; 6 units (booster), Glabella 6/30/93; 22 units, suboccipital (left side) 1/13/94; 22 units, suboccipital (right side) 4/13/94; 20 units each, Glabella and Bilateral Temporal 6/10/94; 10 units each, Left parietal, left and right suboccipital 9/14/94; 10 units left suboccipital and 20 units bilateral temporal 9/30/94 (Forehead, bilateral temporal and suboccipital injections not into muscle).	Onset - 8 years of age; Cheese/Chocolate/Stress - set off headaches (possibly of migraine origin); Symptoms: Pain "severe", nausea; Frequency: Every 2 weeks until head injury, 7/94. Frequency increased, with additional parietal and suboccipital pain not experienced in past migraine history.	Pt. had a migraine when treated on 4/13/94. Within 30 min. nausea ended; within 1.5 hours, the migraine pain ended. No migraine headache pain for 3 months after each treatment. NOTE: Flaccid paralysis of the corrugator and procerus muscles was achieved on June 11, 1993. However, elimination of pain was not achieved until injections given on 6/30/93. Elimination of headache pain in the left suboccipital region achieved on 1/13/94; elimination of pain in the right suboccipital region achieved 4/13/94. Pain associated with head injury relieved within several hours of injection. However, pt. reports occasional occurrence of

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
38/F	4-5 ibuprofen and other drugs	16 units, Glabella 3/25/94; 20 units, Glabella 4/15/94 18 units, Glabella 6/29/94	Pt. began experiencing frequent severe headache pain (possibly of migraine origin) without premonitory symptoms about 9 years ago.	As of receiving first injection, pt has not had any headache pain for about 6 months. However, the second injection was required to induce flaccid paralysis of muscle.
44/F	Acetomenaphin, 500 mg.	15 units, Glabella 2/18/94; 16 units, Forehead 2/18/94; 23 units, Forehead 9/9/94 (Forehead injection not into muscle).	Suffers severe headaches (possibly of migraine origin) about once a week for last 10 years. Intensity ranges from moderate to extreme. Most headaches appear to be centered in the left temporal area. No premonitory symptoms. Pt. also reported experiencing some pain in the temporal mandibular joint area.	Pt. had one headache in the right temporal area in March, 1994. Otherwise, for about 7 months following the first set of injections, pt. did not experience any headache pain over her forehead and upper frontal cranial region. However, pt. reported having premonitory nausea and other symptoms of migraine. TM Joint pain also relieved on left side of face.

-21-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
36/F	Elavil - 25 mg. 4 times a day; Naprosyn - 500 mg. daily; Indocin - 75 mg.	16 units, Glabella 3/25/84	Pt. suffers from moderate to severe headaches daily. Pt was diagnosed with chronic tension headaches 4 years ago by a neurologist. Pt. had been in several car accidents before experiencing the diagnosed condition. Pt. does not experience premonitory symptoms.	Pt. described condition as being a "minor improvement" of her headache pain.

-22-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
47/F	Aspirin; Vancen- ase*****	16 units, Glabella 1/27/94; 12 units, Glabella 4/15/94; 20 units, Crow's 4/15/94; 15 units, Glabella 8/24/94 (Crow's feet area injection not into muscle)	Onset: 12 years of age, Precipitating Events: Strong odor/heat/bright lights/noises/being startled/and hunger. Hands can become cold or tingling sensations can occur. Becomes nauseated. Occurrence: "Migraine" (severe) headaches - once every 1 - 2 months. Other type of "general" (tension) headache occurs daily. Relief: Vanconase Inhaler (for vasomotor rhinitis)/quiet, dark room.	Pt. reports that she has not had a severe ("migraine") headache since the treatment began. Pt. also reports that she has "general" headache pain only "sporadically" (e.g., decreased in frequency from daily to approx. every 3 days).

-23-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
44/F	Aspirin	16 units, Glabella 4/15/94; 12 units, Glabella 5/27/94	Onset: early 30's. Tension headaches nearly every morning. On a scale of 1 - 10, patient rated her headaches 3 - 4.	During the period between receiving the first and second injections, pt. reports that she did not have any headache pain. Pt. did have a headache on the morning of 5/27/94 (date of 2nd injection) which was relieved by aspirin.

-24-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
41/F	Codeine tablets	18 units, Glabella 4/15/94	<p>Onset: 12 years of age after head trauma.</p> <p>Diagnosed as having migraine headaches triggered by certain smells and muscle spasms.</p> <p>Has premonitory aura which lasts for 20 - 25 minutes. Headache pain occurs with hot flashes, visual disturbances and excessive perspiration.</p> <p>Occurs approximately every 6 weeks. Pt. also reports have less frequent tension headaches.</p>	<p>Pt. reports that she did not experience any migraine headache pain for about 3 months, but is having more frequent tension headaches.</p> <p>Pt.'s ability to contract injected muscles returned before she experienced another migraine headache.</p> <p>Note: Patient came into office with migraine headache. Within 1 hour after injection, the symptoms were relieved.</p>

-25-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
40/F	Aspirin	10 units, Crow's feet area 10/6/93; 15 units, Glabella 10/93; 20 units, Forehead 10/6/93; 20 units, Crow's feet 4/25/94; 8 units, Chin 4/25/94; 20 units, Crow's feet 5/27/94; 15 units, Crow's feet 7/15/94 (Forehead and Crow's feet area injections not into muscle)	Frequent headaches (probably tension headaches).	Since injections given over the course of last 6 months, pt. reports that she has not had any headache pain for approximately 1 year.

-26-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
48/F	Acetaminophren, Ibuprofen	10 units, Glabella 3/8/93; 16 units, Glabella 10/29/93; 16 units, Crow's feet 10/29/93; 20 units, Crow's feet 3/25/94; 16 units, Glabella 8/3/94; 20 units, Crow's feet 8/3/94; 20 units, Glabella 10/24/94 (Forehead and Crow's feet injections not into muscle)	Headache pain (possibly of migraine origin) associated with onset of menstrual cycle.	Without headache pain for the almost 1 1/2 years since the first injection. Pt. reported that her headache symptoms had diminished before flaccid paralysis of injected muscles was induced. Pt. experienced mild headache pain at left temporal site 3 days before injection on 10/24/94.
41/F	Inderal (propranolol HCL) ■	20 units, Glabella 5/6/94; 14 units, Medial Forehead 5/6/94; (Latter injection not into muscle)	Daily headaches for past 7 years. True migraine headache - once every 3 to 6 months.	No follow up report yet available.

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
57/F	2 Tablets Fiorinal (butalbinal) w/Codeine■	10 units, Crow's feet 12/4/92; 20 units, Crow's feet 3/25/94; 15 units, Glabella 3/25/94 (Crow's feet injection not into muscle)	Pt. described headache pain as "a crushing" pain in the forehead and temporal areas that occurs about 1 time/week and is associated with eye strain.	On 3/25/94, pt. reported having no headache pain for first 7 weeks after receiving the first injection. She reported having 1 headache in the 8th week which was "weaker" in severity than headache pain she recalled having prior to receiving the injections.

-28-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
43/F	Aspirin	12 units, Glabella 3/18/94; 24 units, both sides, Glabella (+4 units to both sides, Glabella area) 3/4/94; 36 units, Forehead 6/7/94; 8 units, Lateral Glabella 6/29/94; 20 units, Crow's feet 8/24/94; 16 units, Glabella 9/30/94; 12 units, Medial Forehead 9/30/94 (Crow's feet and forehead injections not into muscle)	Daily headache pain brought on by stress.	Pt. states that for first 6 weeks after Botox injection on March 4, 1993, she did not experience any headache pain. Pt. had "a few" headaches after first 6 weeks, but described them as "much weaker" in severity. However, once muscle mobility (glabella) returned, the frequency of the patient's headaches increased.
50/F	Acetaminophren, cold compresses to forehead; lie down in dark room	10 units, Glabella 2/22/93; 12 units, Glabella 5/7/93; 15 units, Glabella 11/5/93; 16 units, Glabella 5/27/94	Onset: Age 20. Frequency: Regular headaches 3 times per week. Migraine headache - 1 time per month with premonitory auras.	Pt. reports that for 6 months after receiving the first injections she did not have any headaches.

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
41/F	Florinal and Fiorinal with Codeine-; Demerol(meperid-dine HCL); at hospital with severe attack	18 units, Giabella 6/29/94	For the last 7 - 8 years pt. had migraine headaches several times per month with premonitory aura.	3 months after receiving the injection, pt. reports that she has not had a migraine. However, pt. has had 3 headaches which she describes as "mild".
41/F	Aspirin	18 units, Giabella 3/9/94; 20 units, Giabella 7/15/94	Headaches 1 time a week of moderate severity. Area of headache = over frontal region and forehead.	6 months after receiving the first injection, pt. reports that she has not experienced a headache.

-30-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
47/F	Ibuprofen	17.5 units, Glabella 8/3/94; 20 units, Crow's feet 9/30/94; 20 units, Bilateral Temporal 9/30/94 (Crow's feet and temporal injections not into muscle)	Frequent headaches described as a dull ache over forehead, temporal areas and back of head. Pt. also reports some pain in the temporal mandibular joint.	<p>Patient complained of headache at injection site for first 2 days. As of 9/16/94, still having daily headaches. However, patient states a decrease in severity. She still has movement in the glabella area.</p> <p>As of 10/7/94: After injection on 9/30/94 (given to temporal region), pt. reports headache in forehead area eliminated.. TMJ pain also described as being "Improved".</p>

-31-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
37/M	Aspirin; acetaminophen; Percodan (oxycodone HCL)†	20 units, Crow's feet 10/23/92; 29 units, Crow's feet 3/18/93; 8 units, Crow's feet 7/9/93; 17.5 units, Glabella 7/9/93; 20 units, Crow's feet 11/11/93; 15 units, Glabella 12/22/93; 18 units, Glabella 8/3/94; (Crow's feet injections not into muscle)	Age of onset: 28 years. Frequency: about 2 times a week. Signs and Symptoms: Patient reports that she feels pain in her forehead and back of head. Measures taken for relief: dark room, cold compresses, Aspirin, Tylenol, Percodan.	As of 10/7/94; pt. reports having a "mild" headache once every few weeks after receiving first injection.

-32-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
54/F	Imitrex (sumatriptan succinate); Darvon (propoxyphene HCL)o. Taking Imitrex during treatment	16 units, Glabella 8/26/94; 10 units, Right Suboccipital 9/30/94; 20 units, Bilateral Temporal 9/30/94; 10 units, Left Suboccipital 9/30/94 (Latter three not into muscle)	Age of onset: 4 years. Frequency: Daily. Diagnosed as migraine. Precipitating events: heat, using computer, chocolate, stress, allergies to pollen. Signs and Symptoms: Pain in back of neck and flashing lights. Reports 12+ pain on scale of 1-10 when she doesn't take Elavil 25 mg. (Note: patient was using Imitrex daily + 2 Darvons + 10 mg of Valium daily which would give minimal relief to headache).	As of 9/18/94: After initial injection pt. reported a general decrease in headache intensity and no headache pain in glabella area. After second injections (R. suboccip.), patient reported decrease in headache pain at injection site (back of neck on that side) and a further decrease in pain intensity in other areas (i.e. back of eyes and other side of neck). Patient is no longer using Imitrex for pain relief. Has used Darvon or Valium to relieve headache pain only once since last injection and reports that she no longer experiences the onset of migraine on exposure to a precipitating event.

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
45/F	Codeine, Demerol, Fiorinal, acetominophen	15 units, Glabella 9/1/94; 15 units, Forehead 9/1/94; 20 units, Bilateral Temporal 9/30/94 (Latter two not into muscle)	Regular (diagnosed) migraines and frequent tension headaches. Precipitating events: Various things will bring on headaches, such as certain smells, weather changes, cold, etc.	As of 9/16/94: no migraines since temporal injection. However, pt. reports that she still has tension headaches, though describes them as being relatively "mild".
26/F	Dalmane (flurazepam HCL).	18.5 units, Glabella 8/24/94; 20 units each, Glabella and Bilateral temporal (latter not into muscle).	Onset: Age 16 . Regular (diagnosed) migraines and less frequent tension headaches. Headache located in forehead and in back of ears. Pt. experiences classic migraine aura, nausea, vomiting, loss of consciousness at times. Pain radiates over left side of head.	As of 9/19/94 Pt. reported that she still has tension headaches with neck pain, but no forehead pain. Pt. also reports that she has not had a migraine headache since receiving the injection. As of 10/10/94, forehead pain returning. On 10/20 had severe pain in right temporal area, nausea, blurred vision. About 2 hrs. after injections on 10/20, pain and related symptoms gone.

-34-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
28/F	Imitrex	16 units, Glabella 9/30/94; 20 units, Bilaterally into the Crow's feet area 9/30/94 (latter injections not into muscle)	2 different types of headaches. (1) general headache 2-3 times per week. Starts behind eyes and radiates to back and top of head. (2) migraine: diagnosed as migraine at age 13. Frequency: 2 times per month. Starts behind eyes and radiates behind neck. It starts with shiny lights and visual disturbances with classic aura's. If she can take medication prior to onset it may stop it from proceeding to a full cycle.	11/11/94: Patient states that she had no headache since the treatment.

-35-

Age/ Sex	Prior Treatment	Site of Delivery	Presenting Condition	Post Injection Condition
21/F	Aspirin	20 units, Glabella 9/20/94	Pt. has suffered from periodic migraine with light intolerance, nausea and blurred vision for several years, as well as more moderate tension headache pain. Pain primarily localized in frontal and temporal areas.	Since injection, pt. reports that she has not experienced any headache pain.
49/F	Cafergot®; Codeine; Antidepressants; Beta blockers (taking during treatment)	20 units, Glabella 9/30/94; 20 units, Bilateral Temporal 9/30/94; 11/9/94, 20 units, Left Temporal (Latter two injections not into muscle)	Patient has suffered from "vascular migraines" for over 21 years with pain primarily on the right side of her head. Precipitating events: Strong smells, bright lights, certain foods such as cheese, herring thyramine-containing foods, red wine, chocolate, caffeine. Aura and stuffy nose. Symptoms: dizziness, nausea, pain.	As of 10/14/94, pt. reports that she had a migraine on 10/6 without premonitory symptoms that she described as "diminished". However, pt. reported having a severe migraine on 10/12, but stated that the pain was only on the left side of her head. Pt. reported that she has not had any cluster headache pain since receiving second injection.

CLAIMS

1. A method for reduction of pain associated with headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by
5 delivery of the presynaptic neurotoxin into one or more muscles.
2. The method according to Claim 1 wherein the neurotoxin is delivered to one or more muscles of the face, cranium and neck.
3. The method according to Claim 2 wherein the presynaptic neurotoxin is
10 delivered to one or more of the frontalis, corrugator, procerus and bilateral temporal muscles.
4. The method according to Claim 2 wherein the presynaptic neurotoxin is also delivered to one or more muscles of the mammal's back.
5. The method according to Claim 1 wherein the presynaptic neurotoxin is
15 administered by electromyographical injection into the muscle.
6. The method according to Claim 1 wherein the presynaptic neurotoxin is administered by injection into muscle in the area of a neuromuscular junction.
7. The method according to Claim 1 wherein the presynaptic neurotoxin is a Botulinum toxin.
- 20 8. The method according to Claim 6 wherein the Botulinum toxin is Botulinum toxin A.
9. The method according to Claim 1 wherein the presynaptic neurotoxin is a biologically active fragment of a proteinaceous toxin.
10. The method according to Claim 8 wherein the biologically active fragment
25 is the Ibc fragment of the Tetanus toxin.


-37-

11. A method for reduction of symptoms associated with the onset or presence of headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin into one or more muscles.
12. A method for reduction of pain associated with headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin to an extramuscular site of the face, cranium or neck.
13. The method according to Claim 12 wherein the neurotoxin is delivered to one or more target sites of the headache pain experienced by the mammal.
14. The method according to Claim 13 wherein the presynaptic neurotoxin is delivered to one or more of the frontal, temporal and suboccipital areas of the face.
15. The method according to Claim 12 wherein the presynaptic neurotoxin is administered by perivascular injection.
16. The method according to Claim 12 wherein the presynaptic neurotoxin is administered by subcutaneous injection.
17. The method according to Claim 12 wherein the presynaptic neurotoxin is a Botulinum toxin.
18. The method according to Claim 17 wherein the Botulinum toxin is Botulinum toxin A.
19. The method according to Claim 12 wherein the presynaptic neurotoxin is a biologically active fragment of a proteinaceous toxin.
20. The method according to Claim 19 wherein the biologically active fragment is the Ibc fragment of the Tetanus toxin.

-38-

21. A method for reduction of symptoms associated with the onset or presence of headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin to an
- 5 extramuscular site in the face, cranium or neck.

1/1



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/05422

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/10, 38/04

US CL :514/2, 14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN (REG, CAS, MEDLINE, BIOSIS)

search terms: tetanus toxin, botulinum toxin, neurotoxin, headache, migraine, pain, algesia, reduce, decrease, diminish, toxoid

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIOLOGICAL ABSTRACTS, Volume 90, No. 7, issued 01 October 1990, Jedynak et al, "Treatment of spasmodic torticollis by local injections of botulinum toxin", see page 867, column 1, abstract no. 79336, Rev. Neurol. (Paris), 146(6/7), 440-443.	1-21
Y	BIOLOGICAL ABSTRACTS, Volume 97, No. 3, issued 15 February 1994, Yakovleff et al, "Indications and use of botulinic toxin in the treatment of spasticity", see page 737, column 2, abstract no. 33434, Annales de Readaptation et de Medecine Physique, 36(5), 359-363.	1-21

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 JULY 1995

Date of mailing of the international search report

25 JUL 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ARVIS & K. MACMILLAN

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US95/05422**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MEDLINE ABSTRACTS, issued 1992, Anderson et al, "Botulinum toxin treatment of spasmodic torticollis", abstract no. 93059130, J. R. Soc. Med., 85(9), 524-529.	1-21